There are 3162 resources available
1951P - A multicenter, retrospective study of non-small-cell lung carcinoma (NSCLC) harboring EGFR exon 20 insertions: Distribution, variants, and prevalence of coalterations
Presenter: Ivana Gabriela Sullivan
Session: Poster session 12
1952P - Multiomic spatial profiling of whole-slide NSCLC tissues from patients receiving anti PD-1 therapy identifies metabolic phenotypes associated with therapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 12
1953P - The ATXN3-USP25-TRMT1 axis regulates tRNAm2,2G modification and promotes osimertinib resistance in lung cancer
Presenter: Tianqing Chu
Session: Poster session 12
Resources:
Abstract
44P - Chemo-immunotherapy combination of mFOLFOX6, bevacizumab and atezolizumab after first-line therapy for advanced biliary tract cancer: The COMBATBIL imCORE trial
Presenter: Mariano Ponz-Sarvise
Session: Poster session 13
47P - First-line pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC) in the China subpopulation from the phase III KEYNOTE-966 study
Presenter: Shukui Qin
Session: Poster session 13
48P - Pattern of expression, transcriptional states and clinical implications of tumour-infiltrating lymphocytes (TILs) in curatively-treated cholangiocarcinoma (CCA) patients (pts): The TILBIL study
Presenter: Maria Pia Quitadamo
Session: Poster session 13
49P - Prognostic relevance of baseline exosome-delivered PD-1, PD-L1, pan-BTN3As and BTN3A1 in advanced cholangiocarcinoma patients: Can immune checkpoints act as a sentinel for predicting survival?
Presenter: Lidia Rita Corsini
Session: Poster session 13
50P - Camrelizumab (Cam) combined with gemcitabine and cisplatin (GP) plus low-dose apatinib in first-line treatment of advanced biliary tract cancer (BTC)
Presenter: yunxin lu
Session: Poster session 13